Attached files
| file | filename |
|---|---|
| EX-12.1 - EXHIBIT 12.1 - ENDOLOGIX INC /DE/ | elgx-ex121_computationofra.htm |
| EX-32.2 - EXHIBIT 32.2 - ENDOLOGIX INC /DE/ | elgx-ex322_20171231x10k.htm |
| EX-32.1 - EXHIBIT 32.1 - ENDOLOGIX INC /DE/ | elgx-ex321_20171231x10k.htm |
| EX-31.2 - EXHIBIT 31.2 - ENDOLOGIX INC /DE/ | elgx-ex312_20171231x10k.htm |
| EX-31.1 - EXHIBIT 31.1 - ENDOLOGIX INC /DE/ | elgx-ex311_20171231x10k.htm |
| EX-21.1 - EXHIBIT 21.1 - ENDOLOGIX INC /DE/ | elgx-ex211_listofsubsidiar.htm |
| EX-10.23.2 - EXHIBIT 10.23.2 - ENDOLOGIX INC /DE/ | secondamendmenttolease.htm |
| EX-10.23.1 - EXHIBIT 10.23.1 - ENDOLOGIX INC /DE/ | consentassignmentfirstamen.htm |
| EX-10.23 - EXHIBIT 10.23 - ENDOLOGIX INC /DE/ | leaseagreement.htm |
| EX-10.9.2 - EXHIBIT 10.9.2 - ENDOLOGIX INC /DE/ | elgx-ex1092_secondamendmen.htm |
| EX-10.9.1 - EXHIBIT 10.9.1 - ENDOLOGIX INC /DE/ | elgx-ex1091xseparationandc.htm |
| 10-K - 10-K - ENDOLOGIX INC /DE/ | elgx-20171231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Endologix, Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-221401, 333-219758, 333‑214537, 333-206208, 333-190393, 333-187258, 333-168465, 333-160317, 333-152774, 333-136370, 333-122491, 333-114465, 333-52482, 333-72531, 333-59305, 333-42161, and 333-07959) on Form S-8, and (Nos. 333-217602, 333-207615, 333-181762, 333-171639, 333-159078, 333-133598, 333-107286, 333-35343, 333-33997, 333-71053, 333-52474, 333-90960, 333-126710, and 333-114140) on Form S-3 of Endologix, Inc. of our reports dated February 28, 2018, with respect to the consolidated balance sheets of Endologix, Inc. and subsidiaries as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017, the related consolidated financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2017, which reports appear in the December 31, 2017 annual report on Form 10‑K of Endologix, Inc.
/s/ KPMG LLP
March 13, 2018
Irvine, California